Why is biological data so scarce?
Ask a biotech founder what’s slowing them down and you’ll rarely hear “we’ve run out of ideas.” The bottleneck is almost always data. High-quality biological datasets are scarce for reasons that don’t go away with a bigger budget: experiments take months to run, cost a fortune, and are unforgiving: one off variable and an entire batch is wasted. The data that would tell you whether an idea works is precisely the data you don’t have yet, and can’t cheaply get.
Layer on top of that the data you’re not allowed to use. Patient records, clinical measurements and anything touching a real person is locked behind privacy law and ethics approval, for good reason, but with the side effect that the richest datasets are often the least accessible.
What does the data gap actually cost you?
It costs you in three currencies. Time: months waiting on experiments or data access, while your runway shrinks. Money: R&D budget burned on physical iterations that a smarter process would have skipped. And confidence: models trained on datasets that are too small, too skewed, or too narrow to trust, shipped anyway because there was nothing better.
The quiet killer is the third one. A model that looks great on a small, clean dataset and then falls over on the messy reality of the lab doesn’t just waste the work that went into it. It erodes trust in the whole approach.
Can’t you just throw more AI at it?
This is the seductive wrong answer. AI models are powerful, but they’re only as good as the data they’re grounded in. A sophisticated model trained on thin or biased data doesn’t fix the data gap. It launders it, turning “we don’t have enough data” into “we have a confident-looking model that’s wrong at the edges.” More parameters don’t manufacture evidence that was never collected.
So the real problem isn’t a shortage of algorithms. It’s a shortage of trustworthy data. Which means the solution has to operate on the data, not just the model.
Three common responses to the data gap
Faced with the data gap, teams often reach for one of two expensive or unreliable options:
- Brute force. Spend your limited budget running more physical experiments, hoping you stumble onto the right configuration. Thorough, but slow and expensive; your budget runs out long before the search space does.
- Black box. Lean on off-the-shelf AI that performs well in a paper and falls over in the lab, because it was never grounded in the physics or biology of your actual system.
There is another route: define the decision first, then create the evidence needed for that job. Depending on the problem, that may mean building a synthetic dataset or comparing experiments in a digital twin.
Build the dataset, or run the experiment virtually
ALTDATA offers two responses to different data problems. A team may need one or, where the work genuinely connects, both.
Synthetic Data builds a dataset for a defined model or research task. New records are generated from useful patterns in the source data, then checked for fidelity and privacy risk. It is for teams that need data to train, test or stress-test a model when the available evidence cannot be used as it stands.
The Digital Twin compares possible experiments. It uses a model grounded in physics and real measurements to predict outcomes across different conditions, with uncertainty attached. It is for research teams deciding which smaller set of experiments deserves physical testing.
They can work together, but they are not interchangeable. A Digital Twin may generate structured synthetic data as part of its method. A standalone Synthetic Data project delivers a dataset for a separate model or research task.
The data gap is not going away. The practical question is what evidence the next decision requires, and whether that means a usable dataset or a virtual experiment.
Choose the job: explore Synthetic Data to build the dataset, or the ALTDATA Digital Twin to compare experiments.